Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 176 of 6351
-
New drug YL202 targets Hard-to-Treat breast cancers
Disease control Recruiting nowThis study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Phase 2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for lung cancer patients who stopped responding to targeted therapy
Disease control OngoingThis is a randomized, open-label, multicenter Phase 3 clinical study to evaluate SKB264 monotherapy versus pemetrexed in combination with platinum in subjects with locally advanced or metastatic non-squamous NSCLC with EGFR mutation who have failed to EGFR-TKI therapy.
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Double immunotherapy combo aims to boost lung cancer surgery outcomes
Disease control OngoingProspective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Paxlovid tested as a shield against long COVID in 2,000-Person trial
Prevention OngoingThe goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does tre…
Phase 3 • Sponsor: Haukeland University Hospital • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
New pill could shield heart attack survivors from future clots
Disease control CompletedThe purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New lung cancer drug challenges standard treatment in major trial
Disease control OngoingThis trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 com…
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill aims to silence chronic cough that Won't quit
Symptom relief CompletedThis is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Phase 3 • Sponsor: Bellus Health Inc. - a GSK company • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Simple cord milking procedure could protect newborn brains after difficult births
Disease control OngoingAn extension of the CORDMILK trial, the CORDMILK follow-up trial will evaluate the neurodevelopmental outcomes at 22-26 months age of term/late preterm infants who were non-vigorous at birth and received umbilical cord milking (UCM) or early cord clamping (ECC).
Sponsor: Nemours Children's Clinic • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combination aims to save bladders in Muscle-Invasive cancer
Disease control OngoingNeoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to radical cystectomy. Currently, well-documented TMT regime…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
Disease control OngoingA sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control CompletedThis study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic …
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
One shot to stop rabies? new vaccine trial begins
Vaccine OngoingThis is a Phase Ib/II, open-label, head-to-head, age de-escalation dose-escalation, partially randomized trial to study the safety and immunogenicity of the candidate rabies vaccine ChAdOx2 RabG in healthy adults (age 18-45 years) and young children (age 2-6 years). ChAdOx2 RabG …
Phase 1/2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 07:57 UTC
-
Real-Time body sensors could make CPR more effective after cardiac arrest
Disease control CompletedThe proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedb…
Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New heart pump trial offers hope for End-Stage heart failure patients
Disease control OngoingThis study is to evaluate the safety and effectiveness of the Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) used for the treatment of end-stage heart failure.
Sponsor: Shenzhen Core Medical Technology CO.,LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Radioactive drug aims to shrink Hard-to-Treat gut tumors
Disease control OngoingThe purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade…
Phase 3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 26, 2026 16:35 UTC
-
New drug shows promise in lung cancer with brain spread
Disease control OngoingThe study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will self-administer oral entrectinib or crizotinib as described in the protocol and local prescribi…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Astrophysics meets dermatology: AI that maps moles like stars to catch melanoma early
Diagnosis OngoingMelanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals with multiple moles. Total body photography (TBP-high-quality images of the entire sk…
Sponsor: Oxford University Hospitals NHS Trust • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Can a new drug ease the muscle weakness of myasthenia gravis?
Disease control CompletedThe purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New device could fix leaky heart valves without Open-Heart surgery
Disease control OngoingThis is a postmarket clinical follow up study on the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System and the Edwards PASCAL Precision Transcatheter Valve Repair System in transcatheter tricuspid valve repair.
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can the sequence of chemo drugs tip the scales in HER2-negative breast cancer?
Disease control OngoingPhase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Phase 3 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC